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Population monitoring for cancer research
consists of the frequent (or even continu-
ous) gathering of information in a given
population that is relevant to that popula-
tion's cancer risk. This ranges from infor-
mation on exposure (such as real-time
monitoring ofradiation dose in a popula-
tion of radiation workers) or carcinogen-
induced phenotypic changes or adducts to
information on gene mutations, possible
preneoplastic lesions (screening for breast
or thyroid abnormalities in the general
population or in a high-risk population),
and cancer occurrence (monitoring ofcan-
cer incidence or mortality through popula-
tion registries in a geographical area). The
main objectives ofpopulation monitoring
in cancer research are to identify carcino-
genic mechanisms by obtaining more pre-
cise estimates of the extent to which
environmental, lifestyle, and genetic factors
contribute to the human cancer burden
and to prevent cancer by providing infor-
mation to evaluate the carcinogenic poten-
tial of agents in the absence ofsufficient
epidemiological data and by identifying
high risk groups on which to focus preven-
tive action.
With these objectives in mind, it is
desirable that, in the future, population
monitoring for cancer research be carried
out within the framework ofwell-designed
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epidemiological studies (with well-defined
objectives), with sufficient power, and with
information on all factors of interest,
including quantitative data on exposure,
individual response to exposure, and
genetic background. This will allow an
assessment ofthe usefulness ofspecific bio-
logical markers as predictors of exposure
and cancer risk and, most importantly, the
study of genetic susceptibility to cancer
induced by environmental mutagens and
of phenotypic response to these agents.
This will also avoid, or minimize, indis-
criminate collection ofdata and biological
samples without a specific research objec-
tive, which (as discussed throughout this
conference) can give rise to erroneous
interpretations. Finally, it will increase the
cost-effectiveness ofstudies ofbiomarkers.
In the planning and conduct of such
studies, careful consideration must be
given to standardizing study parameters (to
ensure that results can be compared to
those ofother studies), promoting access to
systematically collected historical data
(such as records ofmedical or occupational
exposures), keeping biological samples
against future research developments, and
protecting the confidentiality of personal
information while allowing, within the
framework ofthe study, linkage between all
sources ofinformation on an individual's
exposure, response, and cancer risk.
At present, many ofthe epidemiologi-
cal studies carried out or coordinated by
the International Agency for Research on
Cancer (IARC) are designed in such a
way, and biological samples are collected
in addition to information on exposure
and cancer outcome. An example is the
European Prospective Investigation into
Cancer and Nutrition (EPIC) (1). In that
study, a questionnaire is used to gather
detailed information on food intake; physi-
cal characteristics ofstudy participants are
measured and recorded; blood samples are
taken, separated, and stored (a bar coding
system is used instead ofpersonal identi-
fiers to allowlinkage to the other sources of
data); and the participants are followed up
for cancer. In the future, when cancer cases
occur, blood samples of cases and appro-
priate controls will be analyzed, permitting
the study ofthe role ofgenotypic and phe-
notypic characteristics and ofhormones on
the risk of cancer associated with various
components ofthe diet.
It is important, however, in the plan-
ning ofpopulation monitoring studies, to
remember the limitations of biomarkers
observed to date. They have been discussed
extensively in this conference and are
summarized below.
* At present, despite a decade or more of
intensive work, we still have only a lim-
ited number ofinformative biomarkers.
* The choice ofthe relevant biomarker of
exposure and disease can be difficult.
* A marker is often not specific for a par-
ticular exposure but may indicate expo-
sure to various agents and its level may
varywith age, sex, and lifestyle factors.
* It is not always clear whether a given
marker measures exposure, response, or
the end point ofconcern.
* Many biomarkers are short-lived and
therefore reflect only recent exposures,
whereas information on exposures long
in the past may be more relevant for
cancer risk today.
* Frequent monitoring may be needed to
properly characterize patterns ofexpo-
sure that vary over time.
* The analysis of many biomarkers is
complex and the cost when used on
large numbers of individuals may be
prohibitive.
There has already been considerable
success in the use of biomarkers, particu-
larly markers of exposure. Occupational
exposure to chemicals and radioactivity has
been monitored for decades using blood,
urine, or fecal assays, and such measures
have been used as markers of exposure in
epidemiological studies; response to chemi-
cals has also been monitored, for example,
through liver function tests. Exposure to
viruses has been monitored through detec-
tion ofviral DNA in tumors and antigens
in blood; recent successes in cancer research
include the use of these markers in epi-
demiological studies ofhuman papilloma
virus (HPV) and cervical cancer (2,3) and
ofhepatitis B virus (HBV) and liver cancer
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(4). Hemoglobin, albumin, and, more
recently, DNA adducts have been studied
as markers ofexposure; adducts ofaflatoxin
have been particularly important in estab-
lishing a relation between aflatoxin exposure
and hepatocellular carcinoma risk in
epidemiological studies (4,5).
In conclusion, the careful use of bio-
markers in future large-scale, well-designed
studies will most certainly lead to major
improvement in our understanding of
the mechanisms of carcinogenesis and
thus have important cancer preventive and
public health consequences.
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